var data={"title":"Pentobarbital: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentobarbital: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6751?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">see &quot;Pentobarbital: Drug information&quot;</a> and <a href=\"topic.htm?path=pentobarbital-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentobarbital: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208174\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nembutal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208175\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nembutal Sodium</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054820\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Barbiturate</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Barbiturate</span>;</li>\n      <li>\n        <span class=\"list-set-name\">General Anesthetic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hypnotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054812\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">see &quot;Pentobarbital: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adjust dose based on patient's age, weight, and medical condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Consider the potential for delayed metabolism or elimination in infants &lt;6 months of age (Krauss 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypnotic: </b>Children: IM: 2 to 6 mg/kg; maximum dose: 100 mg/dose; <b>Note:</b> Use has generally been replaced by other agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preoperative sedation:</b> <b>Note</b>: Use has generally been replaced by other agents. Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 2 to 6 mg/kg; maximum dose: 100 mg/dose (Krauss 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 to 3 mg/kg every 10 minutes up to a maximum <b>total</b> dose of 6 mg/kg, not to exceed <b>total</b> dose of 100 mg (Cote 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Procedural sedation: Note:</b> Use has generally been replaced by other agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Infants and Children: IM: 2 to 6 mg/kg; maximum dose: 100 mg/dose (Krauss 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Initial: 1 to 2 mg/kg; additional doses of 1 to 2 mg/kg every 3 to 5 minutes to desired effect; usual effective <b>total</b> dose: 1 to 6 mg/kg; maximum <b>total</b> dose: 100 mg/dose (Krauss 2006; Mason 2004). <b>Note:</b> Patients receiving concurrent barbiturate therapy may require higher total mg/kg doses (up to 9 mg/kg) (Mason 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: Oral: 4 mg/kg/dose, if needed supplemental 2 to 4 mg/kg/dose every 30 minutes; maximum <b>total</b> dose: 8 mg/kg (Mason 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children (Krauss 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;4 years: Oral: 3 to 6 mg/kg; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;4 years: Oral: 1.5 to 3 mg/kg; maximum dose: 100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Limited data available (Krauss 2006): Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;4 years: 3 to 6 mg/kg; maximum dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;4 years: 1.5 to 3 mg/kg; maximum dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reduction of elevated ICP:</b> Limited data available: <b>Note:</b> Intubation is required; adjust dose based on hemodynamics, ICP, cerebral perfusion pressure, and EEG.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose: Children and Adolescents: IV: 5 mg/kg every 4 to 6 hours (Mazzola 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose pentobarbital coma: Children and Adolescents: IV: Loading dose: 10 mg/kg over 30 minutes, then 5 mg/kg every hour for 3 hours; initial maintenance infusion: 1 mg/kg/<b>hour</b>; adjust to maintain burst suppression on EEG; maintenance dose range: 1 to 2 mg/kg/<b>hour</b> (Adelson 2003; Rangel-Castillo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation of mechanically ventilated ICU patient (who failed standard therapy):</b> Limited data available: Infants, Children, and Adolescents: IV: Loading dose: 1 mg/kg followed by 1 mg/kg/<b>hour</b> infusion. Additional boluses at a dose equal to hourly rate may be given every 2 hours as needed. If &ge;4 to 6 boluses are administered within 24 hours, then increase maintenance rate by 1 mg/kg/<b>hour</b>; reported required range: 1 to 6 mg/kg/<b>hour</b> (median: 2 mg/kg/<b>hour</b>). Tapering of dose and/or conversion to oral phenobarbital has been reported for therapy &ge;5 days (Tobias 1995; Tobias 2000; Tobias 2000a). <b>Note:</b> Higher rates of adverse effects were observed in a small report that used higher loading and initial maintenance doses (Yanay 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus refractory to standard therapy: Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (AES [Glauser 2016]; NCS [Brophy 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents: Loading dose: 5 mg/kg; maintenance infusion: Initial: 1 mg/kg/<b>hour</b>, may increase up to 3 mg/kg/<b>hour</b> (usual range: 1 to 3 mg/kg/<b>hour</b>); maintain burst suppression on EEG for 24 to 48 hours (no seizure activity), tapering pentobarbital rate by 0.5 mg/kg every 12 hours has been reported (Abend 2008; Holmes 1999; Kim 2001; NCS [Brophy 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose pentobarbital coma: IV: Infants and Children: Loading dose: 10 to 15 mg/kg given slowly over 1 to 2 hours; monitor blood pressure and respiratory rate. Maintenance infusion: Initial: 1 mg/kg/<b>hour</b>; may increase up to 5 mg/kg/<b>hour</b> (usual range: 0.5 to 5 mg/kg/<b>hour</b>); maintain burst suppression on EEG; if the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/hour every 12 hours until burst suppression. A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus (Holmes 1999; NCS [Brophy 2012]). <b>Note:</b> Loading doses of 20 to 35 mg/kg (given over 1 to 2 hours) have been utilized in pediatric patients for pentobarbital coma, but these higher loading doses often cause hypotension requiring vasopressor therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedative/hypnotic/preanesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 150 to 200 mg, as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 100 mg; if needed, may administer additional increments after at least 1 minute, up to a <b>total </b>dose of 200 to 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Seizures:</b> IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 5 to 15 mg/kg administered at a rate of &le;50 mg/minute, may give additional 5 to 10 mg/kg; follow with a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous infusion: 0.5 to 5 mg/kg/hour. If the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/hour every 12 hours. <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208152\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nembutal: 50 mg/mL (20 mL, 50 mL) [latex free; contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (20 mL, 50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (20 mL, 50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208136\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208202\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054826\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: May be administered by deep IM; inject into a large muscle. No more than 5 mL should be injected at any one site because of possible tissue irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV injection: Administer undiluted (50 mg/mL) by slow IV injection; infuse over 10 to 30 minutes not to exceed &gt;50 mg/minute; rapid IV injection may cause respiratory depression, apnea, laryngospasm, bronchospasm, and hypotension; loading doses have been infused over 30 to 180 minutes in head injury patients to decrease the risk of hypotension (Schaible 1982; Wermeling 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Administer at a concentration &le;50 mg/mL via infusion pump; if administering diluted solution monitor for precipitation (Gupta 2001; Sugai 1998). Solution highly alkaline (pH=9.5); care should be taken to avoid extravasation; consider administration using large bore vein (not hand or wrist) or via a running IV line at port farthest from patient's vein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Parenteral solution may be mixed with flavored (eg, cherry) syrup prior to administration to improve palatability (Chung 2000; Mason 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208168\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from freezing and avoid excessive heat. When mixed with an acidic solution, precipitate may form; use only clear solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054825\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Sedation, preanesthetic, short-term treatment of insomnia, and emergency treatment of acute convulsive episodes associated with certain conditions such as status epilepticus, eclampsia, tetanus, cholera, meningitis, and toxic reactions to local anesthetics or strychnine [FDA approved in pediatric patients (age not specified) and adults]; has also been used for procedural sedation (parenteral, oral, and rectal), treatment of increased intracranial pressure, and sedation for the mechanically ventilated ICU patient. <b>Note:</b> The American Academy of Sleep Medicine guidelines recommend against the use of barbiturates such as pentobarbital for the management of insomnia (AASM [Schutte-Rodin 2008]). Although FDA approved for seizures associated with local anesthetics, use has been replaced by other agents (eg, fat emulsion) (Weinberg 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208210\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">PENTobarbital may be confused with PHENobarbital</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nembutal may be confused with Myambutol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Pentobarbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Pentobarbital is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM)  performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208207\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormality in thinking, agitation, anxiety, ataxia, central nervous system stimulation, confusion, depression, dizziness, drowsiness, hallucination, headache, insomnia, nervousness, nightmares, psychiatric disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Exfoliative dermatitis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Megaloblastic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Hyperkinesia, laryngospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea (especially with rapid IV use), hypoventilation, respiratory depression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208159\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to barbiturates or any component of the formulation; porphyria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208140\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: May cause respiratory depression particularly when administered intravenously; use with caution in patients with respiratory disease. Intubation is typically required prior to treatment for seizures or traumatic brain injury (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression or suicidal tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduce dose as appropriate. Do not use in patients showing premonitory signs of hepatic coma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; reduce dose as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Substance abuse: Use with caution in patients with a history of drug abuse; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in patients who are debilitated; marked excitement, depression, and confusion may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; marked excitement, depression, and confusion may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute or chronic pain: Use caution when administering to patients with acute or chronic pain; paradoxical excitement could be induced or important symptoms could be masked.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IV administration: Solution for injection is highly alkaline and extravasation may cause local tissue damage. Too rapid IV administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535372\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child&rsquo;s or fetus&rsquo; brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer&rsquo;s labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208195\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Induces</b> CYP2A6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208145\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12693&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers. <b> Exceptions: </b>Atenolol; Levobunolol; Metipranolol; Nadolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inducers): CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Barbiturates may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbamate: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Felbamate. Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Barbiturates may diminish the therapeutic effect of Progestins (Contraceptive). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Barbiturates may increase the metabolism of Propacetamol. This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of Barbiturates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatostatin Acetate: May enhance the adverse/toxic effect of Barbiturates. Specifically, Somatostatin Acetate may enhance or prolong Barbiturate effects, including sedative effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Barbiturates may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. An anticoagulant dose increase may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208147\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10580824\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Barbiturates can be detected in the placenta, fetal liver and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use of hypnotic doses during labor does not impair uterine activity; however, use of full anesthetic doses decrease the force and frequency of uterine contractions. Respiratory depression may occur in the newborn when sedative-hypnotic barbiturates are administered to the mother during labor; resuscitation equipment should be available, especially for premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054819\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, respiratory status (including pulse oximetry for moderate sedation), cardiovascular status, CNS status, end tidal CO<sub>2. </sub> Monitor EEG when using pentobarbital to treat status epilepticus or to reduce ICP. Monitor ICP and cerebral perfusion pressure (CPP) (CPP = MAP - ICP) when using pentobarbital coma to reduce ICP. Consider monitoring for signs of propylene glycol toxicity (eg, lactic acidosis, acute renal failure, osmolal gap) in patients who require a continuous infusion of pentobarbital. Periodically monitor renal, hepatic, and hematopoietic function with prolonged therapy. If administering diluted solution, monitor closely for precipitation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054824\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypnotic: 1 to 5 mcg/mL (SI: 4 to 22 micromoles/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coma: 20 to 50 mcg/mL (SI: 88 to 221 micromoles/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;10 mcg/mL (SI: &gt;44 &mu;mol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208139\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity; barbiturates produce dose-dependent respiratory depression; reduce brain metabolism and cerebral blood flow in order to decrease intracranial pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F208158\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (Krauss 2006): Children and Adults: Sedation: IM: 10 to 15 minutes; IV: Almost immediate, within 3 to 5 minutes; Oral, Rectal: 15 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (Krauss 2006): Children and Adults: Sedation: IM: 1 to 2 hours; IV: 15 to 45 minutes; Oral, Rectal: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Children: 0.8 L/kg (Schaible 1982); Adults: 1 L/kg (Ehrnebo 1974)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 45% to 70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via hydroxylation and glucuronidation (Wermeling 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Children: 26 &plusmn; 16 hours (Schaible 1982); Adults: Healthy: 22 hours (average)  (Ehrnebo 1974); Range: 15 to 50 hours; dose dependent</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt;1%, as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054831\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Tolerance to hypnotic effect can occur; taper dose to prevent withdrawal; in pediatric patients, a total cumulative pentobarbital dose &ge;25 mg/kg or duration &ge;5-7 days have been reported to have a higher probability of withdrawal. To prevent withdrawal in susceptible pediatric patients, the following dosing approach transitioning to PHENobarbital has been described:  Discontinue PENTobarbital infusion, administer half of the PHENobarbital IV loading dose (see table) over 1 hour followed 6 hours later by the remaining half of PHENObarbital loading dose IV (over 1 hour).  Begin maintenance  PHENobarbital dose 6 hours after loading dose completed; the maintenance PHENobarbital dose should be <sup>1</sup>/<sub>3</sub> of the initial loading dose IV given every 12 hours. Once patient is stabilized, may switch to oral therapy and begin tapering 10% to 20% weekly (Tobias, 2000; Tobias, 2000a). <b> Note:</b> This conversion method is based on preliminary data and further studies are needed to confirm the efficacy of this regimen. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">PENTobarbital Infusion Rate (mg/kg/hour)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">PHENobarbital IV Loading Dose (mg/kg)</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2-3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570484\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nembutal Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $1,512.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (PENTobarbital Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $1,452.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038764\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dormital (UY);</li>\n      <li>Entobar (KR);</li>\n      <li>Medinox Mono (DE);</li>\n      <li>Nembutal (AT);</li>\n      <li>Pentone (AU);</li>\n      <li>Praecicalm (DE);</li>\n      <li>Prodormol (IL);</li>\n      <li>Sombutol (FI);</li>\n      <li>Sopental (ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abend NS and Dlugos DJ, &quot;Treatment of Refractory Status Epilepticus: Literature Review and a Proposed Protocol,&quot; <i>Pediatr Neurol</i>, 2008, 38(6):377-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18486818/pubmed\" target=\"_blank\" id=\"18486818\">18486818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abou Khaled KJ and Hirsch LJ, &quot;Updates in the Management of Seizures and Status Epilepticus in Critically Ill Patients,&quot; <i>Neurol Clin</i>, 2008, 26(2):385-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18514819/pubmed\" target=\"_blank\" id=\"18514819\">18514819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adelson PD, Bratton SL, Carney NA, et al, &quot;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents. Chapter 13. The Use of Barbiturates in the Control of Intracranial Hypertension in Severe Pediatric Traumatic Brain Injury,&quot; <i>Pediatr Crit Care Med</i>, 2003, 4(3 Suppl):S49-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/12847349/pubmed\" target=\"_blank\" id=\"12847349\">12847349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al, &quot;Guidelines for the Management of Severe Traumatic Brain Injury. XI. Anesthetics, Analgesics, and Sedatives,&quot; <i>J Neurotrauma</i>, 2007, 24 Suppl 1:S71-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/17511550/pubmed\" target=\"_blank\" id=\"17511550\">17511550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brain Trauma Foundation, American Association of Neurological Surgeons, and Joint Section on Neurotrauma and Critical Care, &quot;Use of Barbiturates in the Control of Intracranial Hypertension,&quot; <i>J Neurotrauma</i>, 2000, 17(6-7):527-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10937896/pubmed\" target=\"_blank\" id=\"10937896\">10937896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung T, Hoffer FA, Connor L, et al. The use of oral pentobarbital sodium (nembutal) versus chloral hydrate in infants undergoing CT and MR imaging &ndash; a pilot study. <i>Pediatr Radiol</i>. 2000;30:332-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10836598/pubmed\" target=\"_blank\" id=\"10836598\">10836598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehrnebo M, &quot;Pharmacokinetics and Distribution Properties of Pentobarbital in Humans Following Oral and Intravenous Administration,&quot; <i>J Pharm Sci</i>, 1974, 63(7):1114-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/4853598/pubmed\" target=\"_blank\" id=\"4853598\">4853598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer JH and Raineri DL, &ldquo;Pentobarbital Anesthesia for Status Epilepticus,&rdquo; <i>Clin Pharm</i>, 1987, 6(8):601-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/3691007/pubmed\" target=\"_blank\" id=\"3691007\">3691007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta VD. Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. <i>International Journal of Pharmaceutical Compounding.</i> 2001, 5(6): 482-484.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes GL and Riviello JJ, &quot;Midazolam and Pentobarbital for Refractory Status Epilepticus,&quot; <i>Pediatr Neurol</i>, 1999, 20(4):259-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10328273/pubmed\" target=\"_blank\" id=\"10328273\">10328273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim SJ, Lee DY, and Kim JS, &quot;Neurologic Outcomes of Pediatric Epileptic Patients With Pentobarbital Coma,&quot; <i>Pediatr Neurol</i>, 2001, 25(3):217-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/11587876/pubmed\" target=\"_blank\" id=\"11587876\">11587876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krauss B and Green SM, &quot;Procedural Sedation and Analgesia in Children,&quot; <i>Lancet</i>, 2006, 367(9512):766-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/16517277/pubmed\" target=\"_blank\" id=\"16517277\">16517277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mason KP, Zurakowski D, Connor L, et al, &quot;Infant Sedation for MR Imaging and CT: Oral Versus Intravenous Pentobarbital,&quot; <i>Radiology</i>, 2004, 233(3):723-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/15516603/pubmed\" target=\"_blank\" id=\"15516603\">15516603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mazzola CA and Adelson PD, &quot;Critical Care Management of Head Trauma in Children,&quot; <i>Crit Care Med</i>, 2002, 30(11 Suppl):S393-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/12528780/pubmed\" target=\"_blank\" id=\"12528780\">12528780</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller MA, Forni A, and Yogaratnam D, &quot;Propylene Glycol-Induced Lactic Acidosis in a Patient Receiving Continuous Infusion Pentobarbital,&quot; <i>Ann Pharmacother</i>, 2008, 42(10):1502-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18698010/pubmed\" target=\"_blank\" id=\"18698010\">18698010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Millikan D, Rice B, and Silbergleit R, &quot;Emergency Treatment of Status Epilepticus: Current Thinking,&quot; <i>Emerg Med Clin North Am</i>, 2009, 27(1):101-13, ix.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/19218022/pubmed\" target=\"_blank\" id=\"19218022\">19218022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nembutal (pentobarbital) [prescribing information]. Lake Forest, IL: Akorn; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira JK, Burrows PE, Richards HM, et al, &ldquo;Comparison of Sedation Regimens for Pediatric Outpatient CT,&rdquo; <i>Pediatr Radiol</i>, 1993, 23(5):341-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/8233681/pubmed\" target=\"_blank\" id=\"8233681\">8233681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel-Castilla L, Gopinath S, and Robertson CS, &quot;Management of Intracranial Hypertension,&quot; <i>Neurol Clin</i>, 2008, 26(2):521-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18514825/pubmed\" target=\"_blank\" id=\"18514825\">18514825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaible DH, Cupit GC, Swedlow DB, et al, &ldquo;High-Dose Pentobarbital Pharmacokinetics in Hypothermic Brain-Injured Children,&rdquo; <i>J Pediatr</i>, 1982, 100(4):655-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/7062221/pubmed\" target=\"_blank\" id=\"7062221\">7062221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugai K, Sasaki M, Hanaoka S, et al. Practice of pentobarbital therapy in convulsive status epilepticus in children with epilepsy. Epilepsia. 1998; 19(S5):83. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1157.1998.tb01980.x/abstract</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, &quot;Pentobarbital for Sedation During Mechanical Ventilation in the Pediatric ICU Patient,&quot; <i>J Intensive Care Med</i>, 2000, 15:115-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, &quot;Tolerance, Withdrawal, and Physical Dependency After Long-Term Sedation and Analgesia of Children in the Pediatric Intensive Care Unit,&quot; <i>Crit Care Med</i>, 2000a, 28(6):2122-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10890677/pubmed\" target=\"_blank\" id=\"10890677\">10890677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JD, Deshpande JK, Pietsch JB, et al, &ldquo;Pentobarbital Sedation for Patients in the Pediatric Intensive Care Unit,&rdquo; <i>South Med J</i>, 1995, 88(3):290-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/7886524/pubmed\" target=\"_blank\" id=\"7886524\">7886524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury.<i> Drug Intell Clin Pharm</i>. 1987;21(5):459-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/3582175/pubmed\" target=\"_blank\" id=\"3582175\">3582175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wermeling D, Record K, Bell R, et al, &quot;Hemodialysis Clearance of Pentobarbital During Continuous Infusion,&quot; <i>Ther Drug Monit</i>, 1985, 7(4):485-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/4082247/pubmed\" target=\"_blank\" id=\"4082247\">4082247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yaffe K and Lowenstein DH, &quot;Prognostic Factors of Pentobarbital Therapy for Refractory Generalized Status Epilepticus,&quot; <i>Neurology</i>, 1993, 43(5):895-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/8492944/pubmed\" target=\"_blank\" id=\"8492944\">8492944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanay O, Brogan TV, and Martin LD, &quot;Continuous Pentobarbital Infusion in Children Is Associated With High Rates of Complications,&quot; <i>J Crit Care</i>, 2004, 19(3):174-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/15484178/pubmed\" target=\"_blank\" id=\"15484178\">15484178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12693 Version 178.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F208174\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F208175\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054820\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054812\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F208152\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F208136\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F208202\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054826\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F208168\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054825\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F208210\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F208207\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F208159\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F208140\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535372\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F208195\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F208145\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F208147\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10580824\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054819\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1054824\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F208139\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F208158\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1054831\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570484\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038764\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12693|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentobarbital-drug-information\" class=\"drug drug_general\">Pentobarbital: Drug information</a></li><li><a href=\"topic.htm?path=pentobarbital-patient-drug-information\" class=\"drug drug_patient\">Pentobarbital: Patient drug information</a></li></ul></div></div>","javascript":null}